Cardiovascular Research

Post-Acute Sequelae of SARS-COVID-2 Syndrome: Just the Beginning.

Authors: Shereif H Rezkalla|||Robert A Kloner

Affiliations: + Expand

Abstract

Viral diseases are some of the most common infections affecting humans. Despite the unpleasant symptoms, most people return to their normal lives without residual symptoms. Following the acute infectious phase of some viruses, however, in some individuals symptoms may linger to the extent they are unable to return to a normal lifestyle. Following coronavirus disease 2019 infection, significant numbers of patients continued to have symptoms that persisted for months after hospital discharge. Symptoms spanned many organ systems and were prominent in the pulmonary and cardiovascular systems. The exact mechanism is not clear. This group of patients represents a new challenge to our health care systems. An organized, multi-disciplinary approach and further research are warranted to be ready to deliver better care to these patients.

---

Reference List

Davis DJ. Measurements of the prevalence of viral infections. J Infect Dis. 1976;133(Suppl):A3–5. doi: 10.1093/infdis/133.supplement_2.a3.|||Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11:37. doi: 10.1186/1471-2377-11-37.|||Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, Vernon SD, Reeves WC. et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. doi: 10.1136/bmj.38933.585764.AE.|||Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, Cook JR. et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601–615. doi: 10.1038/s41591-021-01283-z.|||Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, Ko FW. et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60(5):401–409. doi: 10.1136/thx.2004.030205.|||Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, Chen L. et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020;8:8. doi: 10.1038/s41413-020-0084-5.|||Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci. 2021;58(5):297–310. doi: 10.1080/10408363.2020.1860895.|||Goertz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, Houben-Wilke S. et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542-2020. doi: 10.1183/23120541.00542-2020.|||Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605. doi: 10.1001/jama.2020.12603.|||Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, Chu HY. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021;4(2):e210830. doi: 10.1001/jamanetworkopen.2021.0830.|||Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, Greenhalgh T. Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. BMC Health Serv Res. 2020;20(1):1144. doi: 10.1186/s12913-020-06001-y.|||Shah AS, Wong AW, Hague CJ, Murphy DT, Johnston JC, Ryerson CJ, Carlsten C. A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax. 2021;76(4):402–404. doi: 10.1136/thoraxjnl-2020-216308.|||Cennimo DJ, Bergman SJ, Olsen KM. Coronavirus disease 2019 (COVID-19) clinical presentation. Medscape. Updated April 2, 2021. Available at: https://emedicine.medscape.com/article/2500114-clinical.|||Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M. et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396–398. doi: 10.1136/thoraxjnl-2020-215818.|||Moreno-Perez O, Merino E, Leon-Ramirez JM, Andres M, Ramos JM, Arenas-Jimenez J, Asensio S. et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021;82(3):378–383. doi: 10.1016/j.jinf.2021.01.004.|||Somani SS, Richter F, Fuster V, De Freitas JK, Naik N, Sigel K, Mount Sinai CIC. et al. Characterization of patients who return to hospital following discharge from hospitalization for COVID-19. J Gen Intern Med. 2020;35(10):2838–2844. doi: 10.1007/s11606-020-06120-6.|||Kazama I. Stabilizing mast cells by commonly used drugs: a novel therapeutic target to relieve post-COVID syndrome? Drug Discov Ther. 2020;14(5):259–261. doi: 10.5582/ddt.2020.03095.|||Lam MH, Wing YK, Yu MW, Leung CM, Ma RC, Kong AP, So WY. et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009;169(22):2142–2147. doi: 10.1001/archinternmed.2009.384.|||Nath A. Long-Haul COVID. Neurology. 2020;95(13):559–560. doi: 10.1212/WNL.0000000000010640.|||Zhong P, Xu J, Yang D, Shen Y, Wang L, Feng Y, Du C. et al. COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms. Signal Transduct Target Ther. 2020;5(1):256. doi: 10.1038/s41392-020-00373-7.|||McDermott CV, Cox EJ, Scanlan JM, Alicic RZ. COVID-19 and gastrointestinal tract symptoms: recognition, containment, and learning from the past. Mayo Clin Proc. 2020;95(11):2320–2324. doi: 10.1016/j.mayocp.2020.08.023.|||Carbajal E. COVID-19 might be triggering new-onset diabetes, researchers say. Hospital Review. February 21, 2021. Available at: https://www.beckershospitalreview.com/patient-safety-outcomes/covid-19-might-be-triggering-new-onset-diabetes-researchers-say.html.|||Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G. et al. New-onset diabetes in COVID-19. N Engl J Med. 2020;383(8):789–790. doi: 10.1056/NEJMc2018688.|||Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med. 2021;31(3):163–169. doi: 10.1016/j.tcm.2020.12.007.|||Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020;17(11):1984–1990. doi: 10.1016/j.hrthm.2020.06.026.|||Umbrajkar S, Stankowski RV, Rezkalla S, Kloner RA. Cardiovascular health and disease in the context of COVID-19. Cardiol Res. 2021;12(2):67–79. doi: 10.14740/cr1199.|||Maleszewski JJ, Young PM, Ackerman MJ, Halushka MK. Urgent need for studies of the late effects of SARS-CoV-2 on the cardiovascular system. Circulation. 2021;143(13):1271–1273. doi: 10.1161/CIRCULATIONAHA.120.051362.|||Pirzada A, Mokhtar AT, Moeller AD. COVID-19 and myocarditis: what do we know so far? CJC Open. 2020;2(4):278–285. doi: 10.1016/j.cjco.2020.05.005.|||Yancy CW, Fonarow GC. Coronavirus disease 2019 (COVID-19) and the heart-is heart failure the next chapter? JAMA Cardiol. 2020;5(11):1216–1217. doi: 10.1001/jamacardio.2020.3575.|||Huang L, Zhao P, Tang D, Zhu T, Han R, Zhan C, Liu W. et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc Imaging. 2020;13(11):2330–2339. doi: 10.1016/j.jcmg.2020.05.004.|||Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174(4):576–578. doi: 10.7326/M20-5661.|||Becker RC. Anticipating the long-term cardiovascular effects of COVID-19. J Thromb Thrombolysis. 2020;50(3):512–524. doi: 10.1007/s11239-020-02266-6.|||Shchendrygina A, Nagel E, Puntmann VO, Valbuena-Lopez S. COVID-19 myocarditis and prospective heart failure burden. Expert Rev Cardiovasc Ther. 2021;19(1):5–14. doi: 10.1080/14779072.2021.1844005.|||Doykov I, Hallqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. 'The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res. 2020;9:1349. doi: 10.12688/f1000research.27287.2.|||Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, Kurz K. et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021;57(4):2003481. doi: 10.1183/13993003.03481-2020.|||Rivera-Morales MD, Pell R, Rubero J, Ganti L. Acute myopericarditis in the post COVID-19 recovery phase. Cureus. 2020;12(10):e11247. doi: 10.7759/cureus.11247.|||Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, Patel R. et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42(19):1866–1878. doi: 10.1093/eurheartj/ehab075.|||Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, Shchendrygina A. et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020;5(11):1265–1273. doi: 10.1001/jamacardio.2020.3557.|||Junttila MJ, Hookana E, Kaikkonen KS, Kortelainen ML, Myerburg RJ, Huikuri HV. Temporal trends in the clinical and pathological characteristics of victims of sudden cardiac death in the absence of previously identified heart disease. Circ Arrhythm Electrophysiol. 2016;9(6):e003723. doi: 10.1161/CIRCEP.115.003723.|||Coromilas EJ, Kochav S, Goldenthal I, Biviano A, Garan H, Goldbarg S, Kim JH. et al. Worldwide survey of COVID-19-associated arrhythmias. Circ Arrhythm Electrophysiol. 2021;14(3):e009458. doi: 10.1161/CIRCEP.120.009458.|||Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–332. doi: 10.1016/j.ijid.2020.09.016.|||Ostergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021;9(3):e14726. doi: 10.14814/phy2.14726.|||Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021;93(2):1013–1022. doi: 10.1002/jmv.26368.|||Marshall M. The lasting misery of coronavirus long-haulers. Nature. 2020;585(7825):339–341. doi: 10.1038/d41586-020-02598-6.|||Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.|||Mahase E. Covid-19: What do we know about "long covid"? BMJ. 2020;370:m2815. doi: 10.1136/bmj.m2815.|||Rovere Querini P, De Lorenzo R, Conte C, Brioni E, Lanzani C, Yacoub MR, Chionna R. et al. Post-COVID-19 follow-up clinic: depicting chronicity of a new disease. Acta Biomed. 2020;91(9-S):22–28. doi: 10.23750/abm.v91i9-S.10146.